Monte Rosa Therapeutics, Inc. [Rocket]

Date Filed

Type

Description

08/18/2023

3

Form 3 - Initial statement of beneficial ownership of securities:

08/15/2023

144

Form 144 - Report of proposed sale of securities:

08/10/2023

10-Q

Quarterly Report for the period ended June 30, 2023

08/10/2023

8-K

Quarterly results

Docs:

"Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update ● On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023 ● Received Orphan Drug Designation from the U.S. Food and Drug Administration for MRT-2359 for the treatment of small cell lung cancer ● Announced development candidate MRT-6160, a novel, highly selective molecular glue degrader of VAV1, with IND submission expected 1H 2024 ● Strong cash position expected to sustain operations into 2025 and enable advancement of pipeline of novel molecular glue degraders BOSTON, Mass., August 10, 2023 –"

07/26/2023

4

Form 4 - Statement of changes in beneficial ownership of securities:

07/26/2023

3

Form 3 - Initial statement of beneficial ownership of securities:

07/26/2023

8-K

Quarterly results

05/11/2023

10-Q

Quarterly Report for the period ended March 31, 2023

05/11/2023

8-K

Quarterly results

Docs:

"Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update • On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the second half of 2023 • Cash runway into 2025 supports operations and advancement of pipeline of novel molecular glue degraders to key inflection points BOSTON, Mass., May 11, 2023 –"

04/26/2023

ARS

Form ARS - Annual Report to Security Holders:

04/26/2023

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:

04/26/2023

DEF 14A

Form DEF 14A - Other definitive proxy statements:

03/31/2023

4

Skvarka Jan (Director) has filed a Form 4 on Monte Rosa Therapeutics, Inc.

Txns:

Granted 41,000 options to buy @ $7.36, valued at $301.8k

03/24/2023

3

Skvarka Jan (Director) has filed a Form 3 on Monte Rosa Therapeutics, Inc.

03/23/2023

8-K

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...

03/16/2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans:

03/16/2023

8-K

Investor presentation, Quarterly results

Docs:

"Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update • Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoing • Disclosure of initial data from Phase 1 arm of study expected in second half of 2023 • MRT-2359 received Fast Track designation from FDA for treatment of patients with previously treated, metastatic non-small cell lung cancer with L-MYC or N-MYC expression • Nomination of multiple development candidates anticipated in 2023 • Year-end 2022 cash balance of approximately $268 million, with cash runway into 2025 BOSTON, March 16, 2023 –",
"NE NCI-H2405 NCI-H1693 NCI-H810 NCI-H1770"

02/14/2023

SC 13G/A

Cormorant Asset Management, LP reports a 6% stake in Monte Rosa Therapeutics, Inc.

02/14/2023

SC 13G/A

PRICE T ROWE ASSOCIATES INC reports a 7.6% stake in MONTE ROSA THERAPEUTICS INC

02/14/2023

SC 13G/A

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

02/09/2023

SC 13G/A

FMR LLC reports a 12.8% stake in MONTE ROSA THERAPEUTICS INC

02/03/2023

SC 13G

Form SC 13G - Statement of acquisition of beneficial ownership by individuals:

01/09/2023

8-K

Investor presentation

Docs:

"0.3 3 30 30 30",
"Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023 • MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer with L-MYC or N-MYC expression • Disclosure of initial data from Phase 1 arm of ongoing Phase 1/2 clinical trial evaluating MRT-2359 expected in second half of 2023 • Nomination of multiple additional development candidates anticipated in 2023 • Company to present pipeline and corporate updates at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 11, 2023, at 11:15 a.m. PT BOSTON, January 9, 2023 – Monte Rosa Therapeutics, Inc. , a biotechnology company developing novel molecu..."

01/04/2023

4

Wallace Owen B. (Chief Scientific Officer) has filed a Form 4 on Monte Rosa Therapeutics, Inc.

Txns:

Granted 135,000 options to buy @ $7.78, valued at $1.1M

01/04/2023

4

Warmuth Markus (President & CEO) has filed a Form 4 on Monte Rosa Therapeutics, Inc.

Txns:

Granted 472,000 options to buy @ $7.78, valued at $3.7M

01/04/2023

4

Nickson Philip (General Counsel) has filed a Form 4 on Monte Rosa Therapeutics, Inc.

Txns:

Granted 123,650 options to buy @ $7.78, valued at $962k

01/04/2023

4

Townson Sharon (Chief Technology Officer) has filed a Form 4 on Monte Rosa Therapeutics, Inc.

Txns:

Granted 78,550 options to buy @ $7.78, valued at $611.1k

01/04/2023

4

Jones Jullian G (Chief Business Officer) has filed a Form 4 on Monte Rosa Therapeutics, Inc.

Txns:

Granted 77,450 options to buy @ $7.78, valued at $602.6k

01/04/2023

4

Castle John C. (Chief Data Scientist) has filed a Form 4 on Monte Rosa Therapeutics, Inc.

Txns:

Granted 78,500 options to buy @ $7.78, valued at $610.7k

01/04/2023

4

Tamboli Ajim (CFO) has filed a Form 4 on Monte Rosa Therapeutics, Inc.

Txns:

Granted 129,850 options to buy @ $7.78, valued at $1M

01/04/2023

4

Janku Filip (Chief Medical Officer) has filed a Form 4 on Monte Rosa Therapeutics, Inc.

Txns:

Granted 135,000 options to buy @ $7.78, valued at $1.1M

12/19/2022

4

Form 4 - Statement of changes in beneficial ownership of securities:

10/24/2022

8-K

Quarterly results

08/11/2022

10-Q

Quarterly Report for the period ended June 30, 2022

Next >>